First PROTAC gains FDA approval, bolstering targeted protein degradation and induced proximity ambitions
nature.com/articles/d41573-0…
Arvinas and Pfizer’s oestrogen receptor degrader vepdegestrant has secured approval for a subset of patients with advanced or metastatic breast cancer